Cargando…
Prevalence of inappropriate use of nirmatrelvir-ritonavir antiviral therapy in hospitalized patients: A multi-centre retrospective study in China
BACKGROUND: Nirmatrelvir-ritonavir (NMVr) is a recently developed antiviral agent for treating coronavirus disease 2019 (COVID-19); however, data describing its appropriate use are scarce. This study examined the prevalence of inappropriate use of NMVr in a Chinese hospital setting. METHODS: A multi...
Autores principales: | Shi, Changcheng, Qiu, Lei, Zhuo, Juanjuan, Fang, Yingying, Wang, Limin, Xia, Junbo, Wang, Shuying, Luo, Qing, Zhou, Kang, Li, Yongchen, Li, Qingyu, Wang, Gang, Lin, Nengming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197429/ https://www.ncbi.nlm.nih.gov/pubmed/37211263 http://dx.doi.org/10.1016/j.ijantimicag.2023.106857 |
Ejemplares similares
-
Ritonavir-boosted Nirmatrelvir and COVID-19 outcomes in the age of Omicron variant
por: Imran, Laiba, et al.
Publicado: (2023) -
Nirmatrelvir-ritonavir for COVID-19
por: McDonald, Emily G, et al.
Publicado: (2022) -
Nirmatrelvir and ritonavir for COVID-19
Publicado: (2022) -
Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
por: Lu, Jiayue, et al.
Publicado: (2023) -
Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir
por: Akinosoglou, Karolina, et al.
Publicado: (2022)